Multipurpose prevention technologies (MPTs) are being designed to deliver multifaceted reproductive health prevention, largely focused on contraception and prevention of human immunodeficiency virus (HIV) and/or other sexually transmitted infections (STIs). They could revolutionize sexual and reproductive health by reducing stigma associated with the need to prevent of HIV and other STIs by incorporating these features into contraceptives, which are less stigmatized [1]. MPTs may also help address increasing concerns about social inequalities and the environment by providing more varied contraceptive choices to help ensure that all children are planned, wanted, and born into healthy families [2]. Support for MPTs has increased over the past decade and their development is endorsed and informed by women, men, civil society, healthcare providers, and policymakers [3–5]. While MPT development is scientifically and logistically complex, financial and technical resources critical for transitioning promising preclinical product candidates/formulations into clinical evaluation remain limited. We contend that this transition requires not only funding, but also technical expertise to inform necessary rigorous criteria and benchmarks to evaluate and advance promising preclinical products into clinical formulations, approved for human testing and poised for clinical trial evaluation. This commentary presents a strategy for bridging MPT funding and development gaps and to advance these products to reach the hands of women.

中文翻译：

---

弥合差距：将多用途预防技术从实验室推进到女性手中†。


多用途预防技术 (MPT) 旨在提供多方面的生殖健康预防，主要侧重于避孕和预防人类免疫缺陷病毒 (HIV) 和/或其他性传播感染 (STI)。他们可以通过将这些功能融入避孕药具中，减少与预防艾滋病毒和其他性传播感染相关的耻辱感，从而彻底改变性健康和生殖健康[1]。 MPT 还可以通过提供更多样的避孕选择来帮助解决对社会不平等和环境日益增长的担忧，以帮助确保所有孩子都得到规划、想要并出生在健康的家庭中 [2]。在过去的十年中，对 MPT 的支持有所增加，其发展得到了女性、男性、民间社会、医疗保健提供者和政策制定者的认可和知情[3-5]。虽然 MPT 开发在科学和逻辑上都很复杂，但对于将有前途的临床前候选产品/制剂转化为临床评估至关重要的财务和技术资源仍然有限。我们认为，这种转变不仅需要资金，还需要技术专业知识，以提供必要的严格标准和基准，以评估有前途的临床前产品并将其推进到临床配方中，批准进行人体测试并准备进行临床试验评估。本评论提出了缩小 MPT 资金和发展差距并推动这些产品到达女性手中的战略。